Using Mounjaro After 30 Days: What the Safety Evidence Shows

The 30-day pen limit: what it means in practice

Every Mounjaro KwikPen contains four weekly doses. Because the pen is used once a week, most patients finish it before the 30-day window closes — but not always. Dose adjustments, a missed week, or advice to delay a dose can leave solution in the pen beyond day 30. The tirzepatide SmPC on the eMC states plainly that the pen must be thrown away 30 days after the first injection, even if doses remain. This is a stability ruling, not a suggestion.

In practice, keeping the pen in the fridge door alongside the things you reliably open every day makes it easier to spot when the 30 days are approaching. Mounjaro should be stored refrigerated between 2 and 8°C; the precise room-temperature window (for travelling or short-term storage) is set out in the Patient Information Leaflet and varies by pen, so check it there rather than relying on any secondary source.

If you think you have used medicine from a pen that was past its 30-day mark, speak to your prescriber before your next injection. It is not an emergency in most cases, but it is the right clinical conversation to have. Our frequently asked questions cover related storage queries, and individual situations are exactly what our prescribers are there for.

How the safety evidence holds up beyond the first month

Concern about longer-term use is understandable. Mounjaro is still a relatively new medicine in the UK, it holds a Black Triangle (▼) designation because regulators want robust post-market data collected as more people use it. That said, the clinical trial programme provides a credible foundation: SURMOUNT-1 followed thousands of adults for 72 weeks, which is roughly 18 months. The NHS's guidance on tirzepatide summarises the known side-effect profile across that window, and the picture is consistent, most adverse effects are gastrointestinal, most are mild to moderate, and most settle over time.

What changes as treatment continues is the dose. The standard schedule starts at 2.5 mg and increases incrementally, typically every four weeks, until the prescriber and patient agree on a maintenance dose. Each step up can bring a short recurrence of early side effects, particularly nausea. This is expected physiology, not a sign something has gone wrong. Knowing it tends to pass reduces the anxiety considerably, which is something the clinical team at our pharmacy can discuss with you during any aftercare contact.

For a thorough look at what the broader tirzepatide safety data show, the tirzepatide safety overview on this site pulls together the key findings in one place.

When to get medical help without delay

Most side effects on Mounjaro are manageable and self-limiting. A handful are not, and recognising them matters. Severe, persistent stomach pain that spreads toward the back (especially accompanied by vomiting) can indicate acute pancreatitis, which the MHRA flagged in a Drug Safety Update issued in January 2026 as an infrequent but serious known risk with GLP-1 medicines. Do not try to wait it out. Seek emergency care.

Other situations that need prompt attention include symptoms of gallbladder problems (sharp pain under the right ribs, particularly after eating), signs of serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing), and dehydration following severe vomiting or diarrhoea. If you want to understand whether Mounjaro is safe to use given a specific health condition or combination of medicines, that question is best put directly to your prescriber. If you develop low mood or thoughts of self-harm, contact your GP or call 111 the same day.

Mounjaro holds a Black Triangle precisely so these signals can be captured systematically. If you experience anything unexpected, report it via the MHRA Yellow Card scheme, patients can submit reports directly, and doing so contributes to the ongoing safety picture for everyone using this medicine. You can also contact our team through our support line, seven days a week.

Making the ongoing-safety decision with your prescriber

The real decision this keyword points to is not just about a pen's expiry date. It is: should I keep going, and is continuing safe for me specifically? That is a clinical question, and it gets a clinical answer, at consultation, at every repeat review, and at any point you raise a concern. The question of how long Mounjaro can safely be taken sits within that same conversation.

At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is approved, a named clinician reads your information, not software. Side effects, dose progression and any new health information are part of that review. It is one of the ways a regulated service differs meaningfully from one that simply posts medicine. If you have questions about whether Mounjaro is safe for your circumstances, or want to understand the process before committing, the free consultation is the right starting point. There is no obligation, and the clinical review happens the same day.

For a wider picture of how Mounjaro sits within the UK's weight-management landscape, including eligibility and costs, the treatment overview covers the ground clearly.